drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Investigational anti-CD20 monoclonal antibody (HS006) that depletes B cells to reduce autoantibody (e.g., anti-PLA2R) production and downstream immune complex/complement-mediated podocyte injury; administered intravenously.
nci_thesaurus_concept_id
C174825
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via immune effector mechanisms (e.g., ADCC/CDC), lowering pathogenic autoantibody (e.g., anti-PLA2R) production and reducing immune complex/complement-mediated podocyte injury.
drug_name
Zuberitamab
nct_id_drug_ref
NCT06642909